Volume 89 Issue 50 | p. 17 | Concentrates
Issue Date: December 12, 2011

Vanderbilt, Janssen Target Schizophrenia

Department: Business
Keywords: academic-industry partnerships, drug discovery, schizophrenia

Schizophrenia drug candidates generated from a two-year-old collaboration between the Vanderbilt Center for Neuroscience Drug Discovery and Janssen Pharmaceuticals will soon be ready for Phase I clinical trials. The candidates use allosteric modulators to adjust the activity of neurotransmitter receptors in the brain. “These drug candidates could lead to a fundamentally new approach to treating schizophrenia,” says P. Jeffrey Conn, codirector of the Vanderbilt center, which has been among the most aggressive . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society